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Aims Inflammation plays a key role in acute coronary syndromes (ACS). Toll-like receptors (TLR) on leucocytes mediate
inflammation and immune responses. We characterized leucocytes and TLR expression within coronary thrombi and
compared cytokine levels from the site of coronary occlusion with aortic blood (AB) in ACS patients.
Methods
and results
In 18 ACS patients, thrombi were collected by aspiration during primary percutaneous coronary intervention.
Thrombi and AB from these patients as well as AB from 10 age-matched controls without coronary artery
disease were assessed by FACS analysis for cellular distribution and TLR expression. For further discrimination of
ACS specificity, seven non-coronary intravascular thrombi and eight thrombi generated in vitro were analysed. In
17 additional patients, cytokine levels were determined in blood samples from the site of coronary occlusion
under distal occlusion and compared with AB. In coronary thrombi from ACS, the percentage of monocytes
related to the total leucocyte count was greater than in AB (47 vs. 20%, P ¼ 0.0002). In thrombi, TLR-4 and TLR-2
were overexpressed on CD14-labelled monocytes, and TLR-2 was increased on CD66b-labelled granulocytes, in
comparison with leucocytes in AB. In contrast, in vitro and non-coronary thrombi exhibited no overexpression of
TLR-4. Local blood samples taken under distal occlusion revealed elevated concentrations of chemokines (IL-8,
MCP-1, eotaxin, MIP-1a, and IP-10) and cytokines (IL-1ra, IL-6, IL-7, IL-12, IL-17, IFN-a, and granulocyte-macrophage
colony-stimulating factor) regulating both innate and adaptive immunity (all P, 0.05).
Conclusion In ACS patients, monocytes accumulate within thrombi and specifically overexpress TLR-4. Together with the local
expression patterns of chemokines and cytokines, the increase of TLR-4 reflects a concerted activation of this inflam-
matory pathway at the site of coronary occlusion in ACS.
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Background
Acute coronary syndromes (ACS) represent the major clinical
events in the natural history of coronary artery disease (CAD).1 Evi-
dence is accumulating that inflammatory processes contribute to the
development of ACS.2–5 Activation of immune cells via different
biological pathways leads to the production of inflammatory
mediators,6 thereby accelerating plaque vulnerability and eventually
rupture. Toll-like receptors (TLR) are key regulators of both
innate and adaptive immune responses.7 Multiple endogenous
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ligands of TLR exist (e.g. heat shock proteins,8 components of extra-
cellular matrix,9 fibrinogen,10 and myeloid-related protein 8/14)11
that activate the TLR signalling network;12 TLR activation induces
the production of proinflammatory cytokines [e.g. interleukin (IL)
6 (IL-6), IL-12, IL-1b, and tumour necrosis factor a (TNF-a)],12,13
chemokines [e.g. IL-8,14 monocyte chemoattractant protein 1
(MCP-1),15 macrophage inflammatory protein (MIP)-1a,16 MIP-1b,
eotaxin,17 and interferon-inducible protein-10 (IP-10)]18 as well as
antimicrobial molecules such as nitric oxide.19 These responses
enable macrophages to eliminate invading microorganisms. Further-
more, after TLR-activation anti-inflammatory cytokines [e.g. IL-1
receptor antagonist (IL-1ra), IL-10, and IL-4]20 are released as well
providing negative feedback regulation of the inflammatory
response. Toll-like receptor-induced expression of co-stimulatory
molecules sustains the activation of adaptive immunity.19
Multiple roles of TLR signalling in atherosclerosis have been pos-
tulated,21 but the involvement of distinct members of the TLR
family in the pathophysiology of ACS remains unknown. Thus,
we investigated in patients with ACS undergoing primary percuta-
neous intervention (PCI) the composition of inflammatory cells as
well as the expression of TLR within the occluding thrombus rela-
tive to the systemic circulation and compared cytokine levels from
the site of coronary occlusion with aortic blood (AB).
Methods
Due to different sampling procedures, cellular analysis with TLR
expression and cytokine levels were studied in two separate study
populations (see Appendix 1). The institutional ethics committee
approved the protocol. Written informed consent was obtained
from all patients.
Cellular analysis and Toll-like receptors
expression
Study population 1
Eighteen ACS patients with aspiration of macroscopically visible red
thrombus during primary PCI and 10 patients with angiographically
documented absence of CAD were consecutively studied.
Sample collection 1
Thrombus material was aspirated from the site of coronary occlusion
during primary percutaneous coronary intervention (PCI) in patients
with ACS using an Exportw XT 6F Aspiration Catheter (Medtronic
Inc., Minneapolis, MN, USA). The harvested thrombi were separated
from blood with a sieve, placed in phosphate buffered saline (PBS),
and immediately processed.
Analysis of cells within thrombi
The cellular content of thrombi and the TLR expression on the different
cell types were assessed in patients with ACS. Thrombi were mechani-
cally disrupted, cells resuspended in cell culture medium RPMI contain-
ing 10% foetal calf serum (FCS) and 0.001% tissue plasminogen activator
(Actilysew, Boehringer Ingelheim Pharma GmbH & Co., Germany) (to
remove fibrin), and rotated for 24 h at 378C before staining. Erythrolysis
was performed by repetitive short mild osmotic shocks. The peripheral
blood or thrombi mixture after incubation for 24 h at 378C with Acti-
lysew were repeatedly incubated with distilled water for 5–10 s; then
PBS was added (1:9 water:PBS) and the cells were centrifuged. This pro-
cedure has been repeated four to five times at 48C to reduce the
amount of red blood cells before the FACS analysis. The cells were
labelled for 1 h at 48C with the primary monoclonal antibodies (or
the respective mixture of fluorochrome-labelled antibodies in the case
of double-labelling) to differentiate leucocyte subpopulations, followed
by 30 min at 48C with the fluorochrome-labelled secondary antibodies
(in the case of single staining) and finally were analysed using a FACSca-
libur (BD Bioscience, Heidelberg, Germany). The following monoclonal
antibodies were used: anti-CD3, CD14, CD19, CD66b (unlabelled or
fluorescein isothiocynate-conjugated, BD Bioscience) and anti-TLR-2,
-3, -4, -9 (phycoerythrine-labelled, eBioscience, San Diego, CA, USA).
Regarding the analysis of the different subpopulations, the first selection
has been done on the basis of the SSC/FSC scatters, differentiating lym-
phocyte, monocyte, and granulocyte/blast gates (quadrant analysis). FL1
and FL2 were compensated, the FITC (FL1) and PE-labelled (FL2) anti-
bodies (for example anti-CD14-FITC and anti-TLR-4-PE) were analysed
separately or in combination. The given subpopulation was selected in
the FL1 quadrant and the intensity of TLR-4 was analysed in a frequency
histogram showing FL2 fluorescence. Mouse IgG1 was used as isotype
control. The proportion of positive cells and median fluorescence inten-
sity (mfi) were determined.
Analysis of aortic blood cells
Cell numbers were analysed using standard procedures (using a Casy1
counter, Scha¨rfe System, Reutlingen, Germany). The same incubation
conditions, labelling procedures, and flow cytometry analysis were
applied for AB cells, as for the cells isolated from thrombi.
Control thrombi
To separate thrombus-specific rather than ACS-specific mechanisms
and to determine potential effects of coagulation products on TLR
expression, we analysed thrombi generated in vitro, and in vivo
thrombi from other clinical settings than ACS.
In vitro thrombi
Peripheral blood samples from eight healthy subjects were separated
into two parts: (i) either 500 mL of blood were incubated with
500 mL recombinant tissue factor (rTF, solution ready to use,
Innovin, Dade-Behring, Marburg, Germany) at 378C in cell culture
media (RPMI-1240 including 10% FCS) for 1–6 h with continuous
rotation to obtain an in vitro thrombus; or (ii) leucocytes were isolated
by Ficoll-paque centrifugation and then incubated with the same con-
centration of tissue factor (to exclude any direct influence of rTF on
the cells). The preparations were incubated for 6 and 12 h at 378C.
The control samples were treated in the same manner as cells of
thrombi from in vivo settings. Cells were extracted using 0.001%
Actilysew stained for CD14 (FITC) and TLR-4 (PE), and analysed by
flow cytometry. Measurements were performed over a time course
from 1 to 12 h.
In vivo thrombi
We collected intravascular thrombi from other clinical settings and
vascular beds than ACS (six peripheral arterial thrombi from patients
with limb ischaemia and one pulmonary embolus) and analysed them
according to the protocol for intracoronary thrombi and in vitro thrombi.
Immunohistochemistry
Immunohistochemistry of intracoronary thrombi was performed on
paraffin-embedded parallel sections on separately collected specimens,
using anti-TLR-4 and anti-TLR-2 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) as primary antibodies. Further, goat anti-mouse bio-
tinylated antibodies and streptavidin conjugated to alkaline
phosphatase (Jackson Laboratories, Bar Harbor, ME, USA) and Dako
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Fast Red Substrate were used. Murine IgG was used as negative control
for primary antibodies. Rheumatoid arthritis synovial membranes were
used as positive controls.
Measurement of cytokine levels
Study population 2
This group consisted of 17 patients presenting with ACS and an ident-
ifiable culprit lesion at angiography during primary PCI plus at least two
of the following three criteria: (i) coronary occlusion, (ii) thrombus for-
mation, (iii) impairment of the wall motion in the supplied territory by
left ventricular angiography. Exclusion criteria were a serum level of
C-reactive protein ≥10 mg/L, myocarditis, pericarditis, or a left ventri-
cular ejection fraction of ≤35%.
Sample collection 2
Serum levels of inflammatory markers were assessed in blood samples
obtained simultaneously from the site of coronary occlusion and the
aorta. In all patients, the culprit artery was intubated with a 7F
guiding catheter and wired with the 0.014 inch PercuSurgeTM
GuardWire
TM
(Medtronic Inc., Minneapolis, MN, USA) as described.6
An Exportw XT aspiration catheter was used to obtain local blood
samples. To minimize potential dilution effects with saline, the
Exportw catheter was immediately inserted without flushing over the
PercuSurge GuardWire with the distal occlusion activated. The aspira-
tion was started at the most distal point and stopped after one passage
at the proximal point of the culprit coronary artery segment. Thus,
only the filling volume of the Exportw catheter might have caused a
minor dilution with AB. This protocol resulted in relatively small
volumes (0.5–2.0 mL) of intracoronary blood, however, sufficient for
processing and analysis with the multiplex technology (see what
follows). Only patients with poor flow (≤ TIMI grade I) after wire
passage were included to ensure preserved local conditions.
Measurement of cytokines/chemokines
and apoptosis markers
Twenty-five cytokines and chemokines were analysed using bead-based
multiplex technology: interleukin-1b (IL-1b), interleukin-1 receptor
antagonist (IL-1ra), IL2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12,
IL-13, IL-15, IL-17, tumour necrosis factor (TNF)-a, interferon
(IFN)-a, IFN-g, granulocyte-macrophage colony-stimulating factor
(GM-CSF), macrophage inflammatory protein (MIP)-1a, MIP-1b,
interferon-g-inducible protein (IP)-10, monokine induced by
interferon-g (MIG), eotaxin, RANTES (regulated on activation, normal
T cell expressed and secreted), and monocyte chemoattractant
protein (MCP)-1 (multiplex detection kit, Biosource International,
Camarillo, CA, USA). The kit contains 96-well microtiter filter plates,
coated with antibodies specific for certain cytokines or chemokines.
Serum concentrations of soluble vascular cell adhesion molecule
(VCAM)-1, soluble intercellular adhesion molecule (sICAM)-1, sFas,
soluble Fas ligand (sFasL); macrophage migration inhibitory factor
(MIF) and tissue plasminogen activator inhibitor (tPAI)-1 were deter-
mined using a multiplex assay capable of simultaneously quantifying
these six analytes (Linco Res. Inc., MO, USA). In addition, C-reactive
protein was measured using a chemiluminescence immunoassay from
Siemens diagnostics (formerly DPC) as previously reported.6
Statistical analysis
Continuous data are presented as median with the interquartile ranges
(IQR). In the figures, data are displayed as box-and-whisker plot (the
smallest observation, lower quartile, median, upper quartile, and
largest observation). A sample size of 10 patients to detect a difference
of 12 mfi units in TLR expression on monocytes (between thrombus
vs. AB) given an alpha error of 0.05 and an error standard deviation
of 10 mfi units would result in a power of 0.92. We used the
Anderson–Darling, D’Agostino Skewness/Omnibus/Kurtosis, Shapiro–
Wilk, Martinez–Iglewicz, and Kolmogorov–Smirnov test to check
the normality. In samples from the same patient, variables were ana-
lysed using the Wilcoxon signed rank test (matched pairs), comparing
samples from different patients we used the Mann–Whitney U-test
(unmatched pairs). Spearman’s rank correlation coefficient was
used to measure the linear relationship between two variables. For
regression-type problems (continuous dependent variable), we actually
computed F-tests (with Bonferroni adjusted P-values). Furthermore,
we used effect size (ES) measures (Cohen’s d; Hedge’s bias correction)
to characterize the strength of the relationship between two variables.
We defined ESs as ‘small, d ≥ 0.2,’ ‘medium, d ≥ 0.5,’ and ‘large, d ≥
0.8’. Statistical analysis was performed with SPSS (version 15; SPSS
Inc., Chicago, IL, USA), NCSS (Kaysville, Utah), and GraphPad Prism
statistical software (GraphPad Software Inc., San Diego, CA, USA).
A P-value , 0.05 was considered statistically significant.
Results
Cellular actors
Study population 1
Eighteen ACS patients with aspiration of macroscopically visible red
thrombus during primary PCI were consecutively studied. TIMI-0
flow (corresponding to a total occluded artery) was present in 17
of 18 patients (95%, TIMI-1 flow in one patient). Mean age was 58
(SD+12) years, 94% were males. No diabetics were included, dys-
lipidaemia was present in 50% of the patients, arterial hypertension
in 44%, 33% had a positive family history for premature cardiovascu-
lar events, and 50% were smokers (Table 1). Twenty-seven per cent
of the patients were on aspirin and clopidogrel-pre-treatment was
rare (6%). GP IIb/IIIa-inhibitors were initiated during PCI in 72% of
the patients (33% abciximab and 39% tirofiban). Heparin was admi-
nistered in 94%, one patient underwent the procedure with dalte-
parine. The AB samples of the control population were taken
from 10 age-matched healthy controls with a similar risk factor
profile and angiographically documented absence of CAD. Patients
with ACS underwent cardiac catheterization on average 4 h after
the onset of symptoms.
Cellular distribution of leucocytes in coronary thrombi
vs. aortic blood
The cellular composition of the intracoronary thrombi from
patients with ACS (study population 1) differed significantly from
blood obtained in the aorta at the same point in time. Almost
half of the cells, on median (IQR) 47% (37–54%) of the leucocytes
within the thrombi were monocytes, whereas the proportion of
these cells in the corresponding AB accounted for only 20% (9–
28%) (P ¼ 0.0002, ES d ¼ 2.3). The second most common leuco-
cytes within the thrombi were T-cells and granulocytes. Within
the thrombi, the percentage of T-cells was significantly lower
[24% (18–31%)] when compared with the AB [34% (30–41%),
P ¼ 0.0035, ES d ¼ 1.3; Figure 1]. The lower percentage of
T-cells within the thrombi was negatively correlated with the
increased percentage of monocytes (Spearman’s rank correlation
coefficient 20.825). Similarly, the percentage of B-cells was
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Table 1 Clinical characteristics of the study populations
Population 1 Population 2
ACS patients (n 5 18) Controls (n5 10) P-value ACS patients (n5 17)
Mean age (years) 59 (+12) 61(+11) 0.33 55 (+2)
Risk factors
Dyslipidaemia 50% 44% 0.30 54%
Hypertension 44% 55% 0.29 42%
Diabetes None None – 33%
Smoking 50% 44% 0.23 58%
Family history 33% 33% 0.28 13%
Previous statin medication 10% 33% 0.16 13%
Clinical presentation
STEMI 77% – 70%
Angiographic degree of CAD
1-vessel disease 45% – 58%
2-vessel disease 30% – 25%
3-vessel disease 25% – 17%
Culprit vessel
LAD 50% – 58%
CX 6% – 29%
RCA 44% – 13%
Lesion characteristics
Total occlusion 94% – 100%
Figure 1 Distribution of leucocytes (%) in coronary thrombi compared with aortic blood samples in patients with acute coronary syndrome.
Increased per cent of monocytes within coronary thrombi compared with monocytes from aortic blood was observed, whereas the per cent of
granulocytes, T- and B-cells was decreased. Data are represented as box-and-whisker plot (the smallest observation, lower quartile, median,
upper quartile, and largest observation).
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lower in the thrombi [2% (1–3%)] compared with the AB [4% (2–
5%), P ¼ 0.0007, ES d ¼ 0.8]. Finally, granulocytes were also less
prevalent within thrombi [mean 23%, median 24% (15–30%)]
than in the AB [mean 35%, median 26% (21–53%), P ¼ 0.002, ES
d ¼ 0.8]. No such differences of local coronary and systemic
levels could be documented for natural killer cells with 3.5%
(2.3–5.4%) in the thrombi vs. 3.4% (2.0–5.5%) in the AB (P ¼
0.85, ES d ¼ 0.1).
Cellular distribution of leucocytes in aortic blood of acute
coronary syndrome patients vs. controls
Absolute total white cell blood count was significantly elevated in
ACS patients [10.8 (8.5–12.7) ×103 per mL compared with 7.4
(5.3–8.8) ×103 per mL in controls; P ¼ 0.0068]. Nevertheless,
on comparison of the percental cellular composition of the AB
of ACS patients with controls, no differences were found for the
proportion either of monocytes (P ¼ 0.62), B-cells (P ¼ 0.68),
natural killer cells (P ¼ 0.87), or granulocytes (P ¼ 0.43). There
was only a trend to an increased percentage of T-cells (P ¼
0.052) in ACS patients (Appendix 2).
Toll-like receptors expression
Leucocytes within coronary thrombi
There was a significantly increased TLR-4 expression [43% (20–
58)] on the leucocytes from the thrombus compared with those
obtained from the AB [24% (19–29%), P ¼ 0.0013, ES d ¼ 1.3].
Similarly, TLR-2 were more markedly expressed [25% (16–52%)]
in leucocytes within the coronary thrombi than in the correspond-
ing AB [22% (10–24%), P ¼ 0.0046, ES d ¼ 0.8]. No such differ-
ences could be documented for the expression of TLR-3 (P ¼
0.19) and TLR-9 (P ¼ 1.0) (Appendix 3).
Aortic leucocytes
The expression of TLR-4 was significantly more pronounced in leu-
cocytes of ACS patients [24% (19–29%)] when compared with
controls [12% (9–15%), P ¼ 0.0012]. No such differences could
be documented either for the expression of TLR-2 (P ¼ 0.23),
TLR-3 (P ¼ 0.11), and TLR-9 (P ¼ 0.11) (Appendix 4).
Toll-like receptors on leucocyte subtypes
FACS analysis revealed a markedly increased TLR-4 median fluor-
escence activity [mfi; 78 (64–85) mfi units] on local CD14+ mono-
cytes obtained from the thrombus compared with aortic
monocytes [65 (57–70) mfi units, P ¼ 0.0061]. Furthermore,
TLR-4 mfi on monocytes of the controls was significantly lower
compared with both thrombus and aortic monocytes of ACS
patients [47 (40–49) mfi units, P, 0.0001]. TLR-2 median fluor-
escence activity on monocytes in the thrombus [153 (126–194)
mfi units] was elevated compared with aortic monocytes of the
same patients [144 (126–159) mfi units, P ¼ 0.041] (Figure 2).
The median fluorescence activity of TLR-2 on CD66b+ granulo-
cytes was similar. Increased TLR-2 mfi was noted on local CD66b+
granulocytes obtained from the thrombus compared with aortic
granulocytes [76 (69–85) mfi units vs. 64 (54–81) mfi units, P ¼
0.002]. TLR-2 mfi on granulocytes of controls was even lower
[48 (43–60) mfi units, P ¼ 0.019]. However, TLR-4 median
fluorescence activity on CD66b+ granulocytes remained unchanged
in the thrombus compared with aortic cells [47 (40–59) mfi units
vs. 47 (41–53) mfi units, P ¼ 0.51] but differed significantly from
controls [30 (29–40) mfi units, P ¼ 0.0008; Figure 2].
Control thrombi
In vitro thrombi
The control samples were treated in the same manner as cells of
the thrombus, i.e. incubation with Actilysew for 24 h at 378C. The
relative proportion of granulocytes is reduced by about 10% with
this procedure, probably due to apoptosis. However, the yield of
cells obtained from thrombi for FACS analysis is increased
thereby. The procedure has no effect on the cell surface
expression of TLR-4, as substantiated in cells before and after
treatment (in three cases). Over a time-course of 12 h, the
expression of TLR-4 on CD14+ monocytes remained in the
same range as previously observed in AB cells from controls
(median mfi: 0 h, 39; 1 h, 41; 2 h, 42; 4 h, 42; 6 h, 39; controls 45).
In vivo thrombi
We collected six thrombi from patients with peripheral arterial
occlusions. Median age was 74 years (range 60–90 years). FACS
analysis revealed a markedly lower TLR-4 median fluorescence
activity [30 (24–39) mfi units] on local CD14+ monocytes
obtained from these arterial thrombi compared with monocytes
from coronary thrombi [78 (64–85) mfi units, P ¼ 0.0004, see
Appendix 5]. Furthermore, we analysed an additional surgically
extracted pulmonary embolus in a 60-year-old patient with deep
venous thrombosis, which demonstrated a comparably lower
TLR-4 expression (52 mfi).
Influence of thrombus age on Toll-like receptor-4
expression
We correlated the age of the thrombi, calculated according to the
patients’ history details, with TLR-4 expression on monocytes.
Regarding the whole timeline of collected thrombi (event-to-
balloon time range from 45 min to 5 days), no significant corre-
lation between TLR-4 mfi on CD14+ monocytes could be
detected (Spearman’s rank correlation coefficient r ¼ 0.32, P ¼
0.18). Even when including only thrombi of a probable age
,12 h (n ¼ 14), the correlation was very weak (Spearman’s rank
correlation coefficient r ¼ 0.45, P ¼ 0.11). Interestingly, in vitro
thrombi (not exposed to their natural environment of cytokines,
extracelluar matrix, necrotic debris, etc.) expressed TLR-4 on
CD14+ monocytes at a still lower level and did not show any
upregulation over the first 12 h (Spearman’s rank correlation coef-
ficient r ¼ 20.23, P ¼ 0.66) (see Figure 3).
Immunohistochemistry
TLR-4 expression was concentrated in distinct regions of the intra-
coronary thrombi (Figure 4). There were groups of mainly mono-
nuclear leucocytes with high expression, whereas in regions with
mainly polymorphonuclear leucocytes almost no TLR-4 activity
was observed. Immunohistochemistry for TLR-2 demonstrated a
reciprocal setting: regions with mainly polymorphonuclear leuco-
cytes showed elevated TLR-2 activity, in contrast to mononuclear
leucocyte clusters. In control thrombi, leucocytes showed gener-
ally a very weak TLR-4 expression. Furthermore, the nested
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appearance of leucocytes observed in intracoronary thrombi was
missing, leucocytes in control thrombi appeared isolated within
filamentous material and erythrocytes (Appendix 6).
Cytokine levels
Patient characteristics of study population 2 are shown in Table 1.
All patients had totally occluded culprit arteries (TIMI-0 flow) at
presentation. Only one patient had prior aspirin medication, no
clopidogrel-pre-treatment was documented. Heparin was used as
anticoagulant in all patients. GP IIb/IIIa-inhibitors were initiated
during PCI in all patients (59% abciximab and 41% tirofiban).
Local concentrations of IL-17 (P ¼ 0.030), GM-CSF (P ¼ 0.013),
IFN-a (P ¼ 0.007), IL-6 (P ¼ 0.008), IL-8 (P ¼ 0.013), MIF (P ¼
0.007), eotaxin (P ¼ 0.019), IL-1ra (P ¼ 0.013), IL-12 (P ¼ 0.001),
MIP-1a (P ¼ 0.001), MCP-1 (P ¼ 0.003), tPAI (P ¼ 0.009), and
IP-10 (P ¼ 0.013) were significantly elevated compared with
aortic levels (Figure 5). The most prominent differences were
identified for IL-12 as evidenced by the highest ES (0.81; power
0.94). No significant concentration gradients were detected for
C-reactive protein (P ¼ 0.62), TNF-a (P ¼ 0.06), IL-1b (P ¼
0.20), IL-10 (P ¼ 0.23), IL-4 (P ¼ 0.06), IFN-g (P ¼ 0.08), MIG
(P ¼ 0.80), RANTES (P ¼ 0.09), MIP-1b (P ¼ 0.14), IL-2 (P ¼
0.22), IL-2R (P ¼ 0.25), IL-7 (P ¼ 0.36), IL-13 (P ¼ 0.06), IL-15
(P ¼ 0.23), sFas (P ¼ 0.83), sFasL (P ¼ 0.06), sICAM (P ¼ 0.55),
and sVCAM (P ¼ 0.18).
Discussion
We have recently shown an increased local formation and
secretion of cytokines such as interleukin-6, serum amyloid A,6
and myeloid related protein 8/1422 (MRP8/14) at the site of coron-
ary occlusion in patients with ACS suggesting that local inflamma-
tory responses are crucial in the development of this syndrome.
However, many cellular sources and pathways of activation of
these processes remain still unclear. In the present study, we
characterize the cellular composition and TLR expression of
occluding coronary thrombi and the local cytokine milieu in
patients with ACS.
Compared with AB, coronary thrombi contained more
CD14-positive monocytes, the most prominent cell type at the
site of occlusion. Accordingly, B-cells and T-cells, as well as gra-
nulocytes, were less prevalent within thrombotic material.
Figure 2 Expression of TLR-4 and TLR-2 on CD14+ monocytes or CD66b+ granulocytes within the thrombi, aortic blood samples of ACS
patients and controls. Markedly increased expression of TLR-4 and TLR-2 was observed on CD14+ monocytes obtained from the thrombus,
when compared with aortic monocytes of the same ACS patients. Increased TLR-2 median fluorescence was noted on local CD66b+ granulo-
cytes from the thrombus, compared with aortic cells. The flow cytometric data from double-labelling (CD14-FITC/TLRs-PE or CD66b-FITC/
TLRs-PE) are represented as box-and-whisker plot (the smallest observation, lower quartile, median, upper quartile, and largest observation).
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Figure 3 Influence of the age of the thrombi on TLR-4 expression. Regarding the whole timeline of collected thrombi (event-to-balloon time
range from 45 min to 5 days), no significant correlation between TLR-4 mfi on CD14+ monocytes could be detected (Spearman’s rank cor-
relation coefficient r ¼ 0.32, P ¼ 0.18). By including only thrombi of suspected age ,12 h (n ¼ 14), there seemed to be a slight increase in
TLR-4 expression over time, but correlation was very weak (Spearman’s rank correlation coefficient r ¼ 0.45, P ¼ 0.11). In in vitro thrombi,
no upregulation over the first 12 h could be documented (Spearman’s rank correlation coefficient r ¼ 20.23, P ¼ 0.66).
Figure 4 Expression of TLR-4 on leucocytes within the intracoronary thrombi. The expression of TLR-4 is concentrated in distinct regions of
the intracoronary thrombi. There are groups of mainly mononuclear leucocytes with high expression (A), whereas in regions with mainly poly-
morphonuclear leucocytes almost no TLR-4 activity was observed (B).
Cellular actors, TLR, and local cytokine profile in ACS 1463
Different levels of CD14-positive monocytes in the peripheral
blood of various ACS subgroups have been described.23 The fact
that monocytes were more prevalent than other leucocytes at
the site of coronary occlusion, however, suggests that they specifi-
cally accumulate in the thrombus on vulnerable plaques and con-
tribute to the inflammatory reactions during coronary occlusion
in ACS. Nevertheless, the origin and the time-course of appear-
ance of monocytes in intracoronary thrombi remain unclear.
Our methodological approach provides a snapshot of the intracor-
onary status at the time of primary PCI for ACS.
Toll-like receptors are expressed in atherosclerotic lesions and
activated plaques.24,25 In our study, also cells within the thrombus
exhibited signs of activation, in particular overexpression of TLR.
Compared with leucocytes in the AB, TLR-4 and TLR-2 were
overexpressed on local CD14-labelled monocytes and TLR-2 on
CD66b-labelled granulocytes. In contrast, no difference was
observed in the expression of TLR-3 and TLR-9 between leuco-
cytes obtained from the thrombus and AB. To clarify, whether
this induction is ACS specific or whether this is an intrinsic
feature of any in vivo thrombus, we correlated the suspected age
of the thrombi with TLR-4 expression on monocytes according
to the duration of clinical symptoms. We do have a considerable
number of early presenters showing a significant activation of the
TLR system in coronary thrombi. No correlation whatsoever can
be shown over time. The fact that TLR were not activated in
monocytes contained in thrombi produced in vitro demonstrates
that the inflammatory milieu at the site of coronary occlusion
specifically upregulates these receptors. The ACS specificity of
TLR-4 overexpression on monocytes at the site of plaque
rupture is further supported by the overexpression of TLR-4 in
coronary thrombi compared with peripheral blood, and with
clots in other settings (peripheral arterial thrombi/emboli and pul-
monary embolus) as described earlier.
The association of CD14 and TLR-4 has been well documented.
Indeed, CD14 is required to streamline LPS-induced signalling on
TLR-4 by assembling with the MD2 protein26 (Figure 6). Further,
TLR-4 and TLR-2 activity is increased on CD14-positive mono-
cytes in patients with CAD and ACS.27– 29 Intracellular signal trans-
duction and cross-talk between TLR-2 and TLR-430 is complex, but
eventually leads to the local release of cytokines and chemokines
with proinflammatory, but also anti-inflammatory properties. Of
note, particularly repetitive low-level activation of the TLR
system could be protective to damage by promoting a pronounced
anti-inflammatory cytokine release to dampen the inflammatory
response during subsequent exposure,20,31 while marked acti-
vation—such as must be the case in ACS—leads to a pronounced
inflammatory response. In monocytes, the TLR-4 and the type I
interleukin-1 receptor (IL-1R) have a unique intracellular TIR
(Toll/IL-1 receptor) signalling domain. In response to activation
by the corresponding ligands, TIR domains interact with the TIR
Figure 5 Locally elevated level of cytokines at the site of plaque rupture in ACS. In study population 2, local concentrations of IL-17, GM-CSF,
IFN-a, IL-6, IL-8, MIF, eotaxin, IL-1ra, IL-12, MIP-1a, MCP-1, tPAI, and IP-10 were significantly elevated compared with aortic levels (all
P, 0.05). Data are represented as box-and-whisker plot (the smallest observation, lower quartile, median, upper quartile, and largest
observation).
C.A. Wyss et al.1464
domain of the cytoplasmatic adaptor proteins. The subsequent
intracellular signalling regulate the production and release of differ-
ent cytokines7,32 (Figure 6). In our study, the cytokine milieu at the
site of coronary occlusion was characterized by elevated concen-
trations of chemokines related to an innate immune response
(e.g. IL-8, MCP-1, eotaxin, MIP-1a, and GM-CSF) and cytokines
regulating adaptive immunity (e.g. IL-12, IL-7, and IL-17).33 The
most prominent differences in local cytokine release were ident-
ified for IL-12, which underlines the important interplay of innate
and adaptive immunity. The production of IL-12 but relative lack
of IL-10 suggests that the local environment around the ruptured
plaque is conducive for Th1 differentiation, which goes very well
together with previously reported findings.34 Interestingly, classic
proinflammatory cytokines such as TNF-a or IL-1b usually
released upon TLR-4 activation by LPS were locally not signifi-
cantly elevated. Similarly, anti-inflammatory cytokines that directly
and negatively regulate TLR-like IL-10 and IL-4 were not elevated
at the site of plaque rupture. Nevertheless, we could observe a
trend towards local elevation of TNF-a (P ¼ 0.06) and IL-4 (P ¼
0.06), which might have become significant without the small
potential dilution effects that cannot be excluded. The locally ele-
vated levels of anti-inflammatory IL-1ra suggest a negative feedback
regulation via the TLR-4-associated IL-1 receptor in the TIR
domain. TLR-4–TLR-2 cross-talk induces a positive feedback
signal leading to sustained and amplified activation30 (Figure 6).
Thus, these results suggest a rather specific pattern of expression
of cytokines and chemokines after TLR activation possibly related
to the endogenous ligands involved in coronary occlusion in ACS.
The present data suggest that the TLR-4 and TLR-2 signalling
pathways on CD14+ monocytes could represent a relevant
signal transduction mechanism of innate immunity which mediates
local vascular inflammation in ACS. In particular, control thrombi
of healthy subjects expressed TLR-4 at lower levels, suggesting
that the overexpression of these receptors on monocytes in
ACS is indeed disease-specific. It has been suggested that the
pleiotropic effects of statins involved in plaque stabilization may
Figure 6 TLR system on monocytes and surrounding cytokine milieu in ACS. Several endogenous ligands to TLR-4 have been postulated.
CD14 is required to streamline LPS-induced signalling on TLR-4 by the MD2-protein. In monocytes, the TLR-4 and the type I interleukin-1
receptor (IL-1R) have a unique intracellular TIR (Toll/IL-1 receptor) signalling domain. In response to the activation by the corresponding
ligands, TIR domains interact with the TIR domain of the cytoplasmatic adaptor proteins. The subsequent intracellular signalling regulates
the production and release of different cytokines. In our study, the cytokine milieu at the site of coronary occlusion was characterized by ele-
vated concentrations of chemokines related to an innate immune response (e.g. IL-8, MCP-1, eotaxin, MIP-1a, and GM-CSF) and cytokines
regulating adaptive immunity (e.g. IL-12, IL-7, IL-17)33.
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be mediated via a reduced expression of TLR-4 on monocytes35
leading to an attenuated immune response. Hypo-responsive
TLR-4 genetic variants have been associated with a reduced risk
of myocardial infarction,36,37 albeit data on TLR-4 polymorphism
are controversial.38,39 Nevertheless, TLR-4 may provide a novel
therapeutic target. Of note, TLR-ligand-based therapies have
been considered recently for drug developement40 and their
therapeutic or preventive effects in infectious, malignant, auto-
immune, and allergic diseases are under evaluation.41 However,
the complexity and redundancy of the TLR-system, as well as
the growing number of endogenous ligands and a number of intra-
cellular signalling molecules and transcription factors regulating
pro- and anti-inflammatory cytokine production and release limit
the predictability of medical interventions within this system.
Thus, a better understanding of the role of TLR ligands and acti-
vation, signalling, and feedback regulation in ACS is necessary.
We acknowledge several limitations of this study. First, we did
only investigate inflammatory pathways and mediators within
thrombi and local blood samples. The inflammatory processes
within the adjacent vessel wall are not addressed in the present
study. The origin of the cells and cytokines accumulating in intra-
coronary thrombi may therefore be either derived from the circu-
lating blood and/or the underlying vulnerable plaque.
Some dilution effect in particular due to the filling volume of the
catheter is likely and cannot be excluded. This raises the question
whether negative findings (such as the lack of significant increase in
TNF-a or IL-1b, IL-10, and IL-4) might be confounded by dilution.
Nevertheless, this limitation does certainly not negate the positive
findings. Assumption of any minimal dilution effect, however, impli-
cates reinforcement of significant elevations.
An ultimate proof for the ACS specifity of TLR upregulation is
beyond the scope of this study. Notwithstanding, when correlating
the calculated age of thrombi with TLR-4 expression, no influence
of thrombus age was found. Although determination of the exact
age of thrombi from other clinical settings than ACS, namely per-
ipheral arterial/pulmonary emboli, is certainly more difficult (prob-
ably they are more often subacute and thus older than coronary
thrombi), the difference in TLR-4 expression was highly significant
and uniform. This finding further supports the ACS specificity of
our findings.
It had been shown previously that antithrombotic therapy can
influence gene expression in monocytes.42 We cannot exclude a
possible influence of an intensified antithrombotic therapy in
ACS patients compared with control patients without antithrom-
botic regimen during catheterization. Nevertheless, in the analysis
of local vs. systemic TLR upregulation on monocytes each patient
is his own control, eliminating therefore a bias in periprocedural
antithrombotic regimen.
Furthermore, there is a variety of pathophysiological variants in
ACS (e.g. plaque morphology, heralded vs. unheralded infarctions,
etc.), which may display different inflammatory reaction patterns
that need further investigations.
In conclusion, monocytes accumulate in ACS patients within
thrombi and markedly and specifically overexpress TLR-4.
Together with the local expression patterns of chemokines and
cytokines, the increase of TLR-4 reflects a concerted activation
of this inflammatory pathway at the site of coronary occlusion in
ACS. Through a better understanding of the role of TLR activation
and signalling in ACS, specific TLR-targeted therapies could be
beneficial in cardiovascular diseases in the future.
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Appendix 1
Due to different sampling procedures, cellular analysis with
TLR-expression and cytokine levels were studied in two separate
study populations.
Appendix 2
Cellular distribution of leucocytes
in aortic blood of ACS patients
vs. controls
No differences were found for the proportion either of monocytes
(P ¼ 0.62), B-cells (P ¼ 0.68), natural killer cells (P ¼ 0.87), or
granulocytes (P ¼ 0.43) comparing the percental cellular compo-
sition of the AB of ACS patients with controls. There was only a
trend to an increased percentage of T-cells (P ¼ 0.052) in ACS
patients.
Data are expressed as per cent of specific leucocytes according
to the total leucocyte count of the sample and represented as
box-and-whisker plot (the smallest observation, lower quartile,
median, upper quartile, and largest observation).
C.A. Wyss et al.1466
Appendix 3
Expression of Toll-like receptors
(TLR) on leucocytes in thrombi,
compared with AB
Significant increase of expression TLR-4 and TLR-2 on leuco-
cytes enclosed within the thrombi compared with those
obtained from the AB (P, 0.01 and P, 0.01, respectively).
No such difference could be found for the expression of
TLR-3 and TLR-9. Data are expressed as per cent of TLR posi-
tive leucocytes according to the total leucocyte count of the
sample and represented as box-and-whisker plot (the smallest
observation, lower quartile, median, upper quartile, and largest
observation).
Appendix 4
Expression of Toll-like receptors
(TLR) on aortic leucocytes of
patients with acute coronary
syndromes (ACS) compared
with healthy controls
Significant increase of TLR-4 expression on aortic leucocytes in
ACS patients compared with healthy controls. No such difference
could be found for the expression of TLR-2, TLR-3, or TLR-9. Data
are expressed as per cent of TLR positive leucocytes according to
the total leucocyte count of the sample and represented as
box-and-whisker plot (the smallest observation, lower quartile,
median, upper quartile, and largest observation).
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Appendix 5
Expression of TLR-4 on monocytes
in coronary and non-coronary
thrombi
We collected six thrombi from patients with arterial occlusions.
FACS analysis revealed a markedly lower TLR-4 median fluor-
escence activity (30 mfi units; IQR 24–39) on local CD14+ mono-
cytes obtained from these arterial thrombi compared with
monocytes from coronary thrombi (78 mfi units; IQR 64–85,
P ¼ 0.0004).
Appendix 6
Expression of TLR-4 on leucocytes
within the in vitro thrombi
In artificial control thrombi, leucocytes showed generally a very
weak expression of TLR-4. Furthermore, the nested appearance
of leucocytes observed in intracoronary thrombi was missing, leu-
cocytes in control thrombi appeared isolated within filamentous
material and erythrocytes without any grouping of leucocytes.
Panel A, surface of the thrombus, with filamentous material;
Panel B, inside of the thrombus, with isolated leucocytes and
mostly erythrocytes; Panel C, isotype negative control (inset).
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Inter-ventricular septal thinning and high-degree atrio-ventricular block
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A 55-year-old woman was referred to our
department for progressive dyspnoea. No per-
sonal nor familial history except a smoking
habit was reported. Electrocardiogram showed
a third-degree atrio-ventricular (A-V) block
with ventricular rate at 35 b.p.m. (Panel A).
Transthoracic echocardiography revealed a
dilated myocardiopathy with ejection fraction
estimated at 35%. Curiously, an abnormally
thin aspect of the basal portion of the inter-
ventricular septum (IVS) was noted. Maximum
thickness was measured at 4 mm (Panel B).
There was no septal defect. Cardiac magnetic
resonance found a pathologically thin septum
with transmural delayed enhancement in that
area (arrows) in favour of a localized septobasal
fibrosis (Panel C).
Confronted to a complete heart block with
poor left ventricular function, a triple-chamber
pacemaker was implanted. Coronary angiogra-
phy revealed the absence of septal branch
arising from the left descending artery before
the origin of the first diagonal (Panel D). Blood
tests were normal including troponin T and
Lyme disease serology.
Three months later, the patient is found symptomless and NYHA class I. Echocardiography confirms the same aspect of the IVS with
ejection fraction slightly improved at 40%.
To our knowledge, this observation is the first to describe a third-degree A-V block relevant of a missing septal branch with loca-
lized septal thinning. Aetiology remains imprecise, no patent argument was found for an acute coronary syndrome and isolated agen-
esis of a septal branch has never been noted. The origin of the myocardiopathy is also unknown and a prolonged A-V block could be
incriminated.
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